Roche Legal Worries Aside, Amgen Posts Solid Earnings

As some investors fidget over the outcome of an erythropoietin lawsuit against F. Hoffmann-La Roche Ltd., Amgen Inc. posted estimate-beating third-quarter numbers, with earnings of $1.1 billion, or 94 cents per share, compared to $967 million, or 77 cents per share, during the same period last year. (BioWorld Today)